Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) Sees Large Growth in Short Interest

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 2,235,900 shares, a growth of 59.8% from the May 31st total of 1,399,600 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is currently 96.0 days.

Telix Pharmaceuticals Trading Down 0.2 %

Shares of OTCMKTS:TLPPF traded down $0.03 during trading on Friday, hitting $12.65. 15,772 shares of the company’s stock traded hands, compared to its average volume of 7,871. Telix Pharmaceuticals has a 52 week low of $5.30 and a 52 week high of $13.50. The company has a 50-day moving average price of $10.91 and a 200-day moving average price of $8.73.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.